Trials / Not Yet Recruiting
Not Yet RecruitingNCT07159009
A Study of GB261 in Systemic Sclerosis
An Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of GB261 in Systemic Sclerosis
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of GB261 in patients with SSc.
Detailed description
An Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of GB261 in Systemic Sclerosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Biological: GB261 | GB261 will be dosed according to the protocol |
Timeline
- Start date
- 2025-09-04
- Primary completion
- 2026-12-01
- Completion
- 2027-07-31
- First posted
- 2025-09-08
- Last updated
- 2025-09-08
Source: ClinicalTrials.gov record NCT07159009. Inclusion in this directory is not an endorsement.